Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio will Market Lilly's Recombinant Insulin in China

publication date: May 17, 2017

3SBio of Shenyang entered a strategic cooperation agreement with Lilly China under which 3SBio will promote and distribute Lilly's well-established Humulin®, an insulin product. Originally formulated in 1982, Humulin was the first recombinant insulin product in the world. It has been available in China since 1997. In October 2016, 3SBio paid $100 million for rights to market two AstraZeneca diabetes products in China: Byetta and Bydureon, both of which are injectable Glucagon-Like Peptide-1 antagonists for type 2 diabetes. More details....

Stock Symbols: (HK: 1530) (NYSE: LLY) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital